Completed Clinical Trials

Below is information on clinical trials of our products conducted at leading medical institutions in Uzbekistan.

Trial 1

Bacteriophage Staphylococcal Liquid "MediPHAGE"

Study title: Study of the clinical efficacy and tolerability of "Bacteriophage Staphylococcal Liquid MediPHAGE" (20 ml vials) in patients with purulent-inflammatory soft tissue diseases
Site: City Clinical Hospital No. 1 named after Abu Ali ibn Sino, purulent surgery department
Date: 2016
Details: The clinical trial was conducted in 2016 at City Clinical Hospital No. 1 named after Abu Ali ibn Sino, in the purulent surgery department.
Study leadership: Principal investigators: M.A. Kulabduallayeva, A.B. Bobojonov

Trial 2

Study title: Open clinical trial on the efficacy and tolerability of "Bacteriophage Dysentery Polyvalent MediPHAGE" (20 ml vials for oral and rectal use), manufactured by Aziya Immunopreparat LLC, Uzbekistan
Site: Republican Specialized Scientific-Practical Medical Center of Epidemiology, Microbiology, Infectious and Parasitic Diseases
Date: October 4, 2025
Details: The open clinical trial was conducted on 4 October 2025 at the Republican Specialized Scientific-Practical Medical Center of Epidemiology, Microbiology, Infectious and Parasitic Diseases.
Study leadership: Trial director: PhD Zh.D. Tuychiyev; investigator: department head D.K. Nabikhodzhayeva

Trial 3

Study title: Study of the clinical efficacy and tolerability of "Polyvalent Salmonella Bacteriophage MediPHAGE" (capsules and 20 ml liquid vials for oral and rectal use), manufactured by Aziya Immunopreparat LLC, Uzbekistan
Site: Republican Specialized Scientific-Practical Medical Center of Epidemiology, Microbiology, Infectious and Parasitic Diseases
Details: The clinical trial was also conducted at the Republican Specialized Scientific-Practical Medical Center of Epidemiology, Microbiology, Infectious and Parasitic Diseases.

Trial 4

Study title: Open controlled randomized clinical trial on the efficacy and tolerability of "Protephag Polyvalent" (20 ml vials for oral, local and external use, and spray for topical use), manufactured by Aziya Immunopreparat LLC, Uzbekistan
Site: Tashkent State Medical University, Department of General Surgery
Date: June 17, 2026
Details: The open controlled randomized clinical trial was conducted on 17 June 2026 at Tashkent State Medical University, Department of General Surgery.
Study leadership: Director: Head of the Department of General Surgery, Professor A.O. Okhunov, MD. Investigator: Associate Professor U.K. Kasimov, PhD